Panbela Therapeutics Inc. (PBLA)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Panbela Therapeutics Inc. (“Panbela" or "the Company") (NASDAQ: PBLA). The investigation concerns whether Panbela and certain of its officers and/or directors have violated federal securities laws.
On February 10, 2021, Panbela issued a press release announcing an update on the Company’s current clinical trial for its proposed pancreatic cancer treatment SBP-101, disclosing that “Panbela’s independent data safety monitoring board (DSMB) recommended SBP-101 be held for ongoing patients in order to obtain additional safety information but will continue with the standard drug regimen[.]” Panbela advised that “[s]ome patients in the trial were noted to have complaints of visual changes, although visual changes were not seen in the SBP-101 monotherapy study” and that the Company “continues to be in communication with the trial investigators regarding the recommendation . . . to hold administration of SBP-101 pending further investigation of visual disturbance adverse events.” On this news, Panbela’s stock price fell $2.18 per share, or 26.59%, to close at $6.02 per share on February 10, 2021.
If you are aware of any facts relating to this investigation, or purchased Panbela shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.